These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31866282)

  • 1. Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia.
    Buske C
    Lancet Haematol; 2020 Feb; 7(2):e85-e86. PubMed ID: 31866282
    [No Abstract]   [Full Text] [Related]  

  • 2. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.
    Owen RG; McCarthy H; Rule S; D'Sa S; Thomas SK; Tournilhac O; Forconi F; Kersten MJ; Zinzani PL; Iyengar S; Kothari J; Minnema MC; Kastritis E; Aurran-Schleinitz T; Cheson BD; Walter H; Greenwald D; Chen DY; Frigault MM; Hamdy A; Izumi R; Patel P; Wei H; Lee SK; Mittag D; Furman RR
    Lancet Haematol; 2020 Feb; 7(2):e112-e121. PubMed ID: 31866281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib in the management of Waldenstrom macroglobulinemia.
    Yosef A; Touloukian EZ; Nambudiri VE
    J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
    Furman RR; Luan Y; Bilotti E; Graef T
    Leuk Lymphoma; 2017 Jun; 58(6):1502-1505. PubMed ID: 27784188
    [No Abstract]   [Full Text] [Related]  

  • 5. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
    Argyropoulos KV; Palomba ML
    Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Agents in Waldenström Macroglobulinemia.
    Sarosiek S; Castillo JJ
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):751-760. PubMed ID: 37198054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review.
    Moore DC
    J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing BTK Inhibition in Waldenström Macroglobulinemia.
    Sarosiek S; Castillo JJ
    J Natl Compr Canc Netw; 2024 May; 22(4):. PubMed ID: 38754469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions.
    Owen RG
    J Clin Oncol; 2021 Feb; 39(6):548-550. PubMed ID: 33444081
    [No Abstract]   [Full Text] [Related]  

  • 10. Inflammation is predictive of outcome in Waldenström macroglobulinemia treated by Bruton tyrosine kinase inhibitors: a multicentric real-life study.
    Debureaux PE; Forgeard N; Elessa D; Harel S; Frenzel L; Royer B; Talbot A; Choquet S; Davi F; Nguyen-Khac F; Cuccuini W; Cheminant M; Bravetti C; Lazarian G; Kaltenbach S; Hermine O; Roos-Weil D; Espéli M; Balabanian K; Arnulf B
    Haematologica; 2024 Jan; 109(1):325-330. PubMed ID: 37584289
    [No Abstract]   [Full Text] [Related]  

  • 11. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Waldenström macroglobulinemia in 2020.
    Castillo JJ; Treon SP
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
    Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP
    Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
    Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
    Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.
    Zanwar S; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2020 Feb; 15(1):31-43. PubMed ID: 32006301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Waldenström macroglobulinemia.
    Baďurová K; Gregorová J; Vlachová M; Krejčí M; Ševčíková S
    Klin Onkol; 2021; 34(6):428-433. PubMed ID: 34911327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A safety profile of medications used to treat Waldenström's macroglobulinemia.
    García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
    Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Zent CS; Brady MT; Delage C; Strawderman M; Laniewski N; Contant PN; Kanagaiah P; Sangster MY; Barr PM; Chu CC; Topham DJ; Friedberg JW
    Leukemia; 2021 Jun; 35(6):1788-1791. PubMed ID: 33128020
    [No Abstract]   [Full Text] [Related]  

  • 20. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
    Treon SP; Castillo JJ; Skarbnik AP; Soumerai JD; Ghobrial IM; Guerrera ML; Meid K; Yang G
    Blood; 2020 May; 135(21):1912-1915. PubMed ID: 32302379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.